[PDF] Top 20 Rev. Bras. Hematol. Hemoter. vol.32 suppl.2
Has 10000 "Rev. Bras. Hematol. Hemoter. vol.32 suppl.2" found on our website. Below are the top 20 most common "Rev. Bras. Hematol. Hemoter. vol.32 suppl.2".
Rev. Bras. Hematol. Hemoter. vol.32 suppl.2
... Este fascículo da RBHH apresenta um conteúdo extenso e atualizado sobre o estado da arte da deficiência de ferro, e inclui artigos que descrevem a prevalência desta alteração hematológic[r] ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.32 suppl.2
... Anemia é comum em idosos e é associada a significante morbidade e mortalidade. Mais de 10% dos indivíduos acima de 65 anos tem anemia. Com uma proporção crescente da população mundial atingindo idade igual ou superior a ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... To evaluate the efficacy of high-dose therapy and ASCT in the treatment of Follicular Lymphoma (FL) a randomized multicenter trial comparing intensive therapy vs. conventional chemotherapy, both supplemented with ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... phase 2 = during HCT and phase 3 = maintenance therapy or in ...Phase 2, the risk factors were central venous catheters, neutropenia and mucositis; bacteremia (31%) and fever of unknown origin (23%) were ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... 1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... time of diagnosis, age (< 60 years), performance status (ECOG PS 2 or higher), LDH level above upper normal range, and bone-marrow involvement were identified as independent predictors in OS. In addition to ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... Adult lymphoblastic lymphoma (LBL) is a rare disease which represents less than 2% of all non-Hodgkin's lymphomas (NHL). More than 80% of adult LBL, which is more common in adolescents and young patients, have a ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... 6. Roukis TS, Zgonis T, Tiernan B. Autologous platelet-rich plasma for wound and osseous healing: a review of the literature and commercially available products. Adv Ther. 2006;23(2):218-37. 7. Schnabel LV, ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... For the multivariate analysis two variables remained: LDH (as categorical variable - Hazard ratio - HR = 2.41; 95% CI: 1.04- 5.59; P = 0.04) and DP after HDCY (HR = 3.97; 95% CI: 1.73-9.10; P = 0.001). In summary, 65% ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... sobrevida global de 44%, as altas taxas de mortalidade relacionadas ao procedimento convenceram a maioria dos hematologistas que esta não é uma opção real para pacientes com DH. O desenvolvimento do transplante de ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... 2. de Souza CA, Pagnano KBB, Lorand-Metze I, Miranda ECM, Baldissera R, Aranha FJP, et al. Brazilian experience using high dose sequential (HDS) followed by autologous Hematopoietic Stem Cell Transplantation ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... the suggested hypothesis that a new and more tolerant immune system is generated after the treatment, explaining the reduction of autoimmune destruction and clinical improvement (Mechanism #2, Table 2). ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... cyclophosphamide, and rituximab (FCR) combination therapy produces the largest proportion of complete responses (CRs) ever reported in CLL and, even more importantly, patients treated with this regimen have better ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... Modificações na estratégia terapêutica da AAS ocorreram nas últi- mas décadas. Terapêutica imunossupressora (TIS) mantém-se ba- seada na combinação de globulina antitimocitária e ciclosporina com ou sem G-CSF. A idade, ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... second generation TKI as second line therapy awaits to be verified. In contrast, the major risk of the second strategy derives from the fact that it has recently been demonstrated that compound mutants (2 or 3 ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis. 1985;15(2):126-33. 32. Di Bona E, Avvisati G, Castaman G, Luce Vegna M, De Sanctis V, Rodeghiero F, ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... populations; 2) it can define the lineage affiliation; 3) it can identify sets of genes that characterize subsets of patients with distinct responses to treatment and, ultimately, have a prognostic impact; 4) it ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... In a recent retrospective study (15), RIC was compared to myeloablative conditioning. RIC was associated with lower non-relapse mortality at 2 years (24% vs. 37%) but a higher relapse rate (54% vs. 27%) compared ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... The Durie/Salmon staging system continues to be used worldwide in patients with multiple myeloma. However, in recent years, new systems have been proposed. The International Myeloma Working Group performed a ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... a 2-(CHOP- 14) or 3-weeks (CHOP-21) schedule and the addition of etoposide (CHOEP), also on a 2- or 3-week schedule, in young (18 to 60 years) (NHL-B1) and elderly (>60 years) (NHL-B2) patients with ... See full document
5
temas relacionados